VRDN Viridian Therapeutics Inc
Price (delayed)
$13.07
Market cap
$1.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$986M
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal
Highlights
The equity has soared by 52% YoY but it fell by 5% QoQ
Viridian Therapeutics's EPS has increased by 21% YoY but it has decreased by 6% QoQ
VRDN's quick ratio is down by 18% since the previous quarter and by 16% year-on-year
The net income has contracted by 14% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of VRDN
Market
Valuations
Earnings
Shares outstanding
81.48M
Market cap
$1.07B
Enterprise value
$986M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
2,937.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,264.89
Revenue
$302,000
Gross profit
$302,000
Operating income
-$299.04M
Net income
-$269.95M
EBIT
-$266.9M
EBITDA
-$266.19M
Free cash flow
-$232.83M
Per share
Balance sheet
Liquidity
EPS
-$3.07
EPS diluted
-$3.07
Free cash flow per share
-$3.43
Book value per share
$8.48
Revenue per share
$0
TBVPS
$10.94
Total assets
$742.4M
Total liabilities
$70.76M
Debt
$20.58M
Equity
$671.64M
Working capital
$690.59M
Debt to equity
0.03
Current ratio
15.43
Quick ratio
14.99
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-88,143%
Gross margin
100%
Net margin
-89,387.1%
Operating margin
-99,018.2%
Return on assets
-39.5%
Return on equity
-43.3%
Return on invested capital
-49.4%
Return on capital employed
-38.4%
Return on sales
-88,378.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRDN stock price
How has the Viridian Therapeutics stock price performed over time
Intraday
4.06%
1 week
-7.7%
1 month
-15.84%
1 year
-21.69%
YTD
-31.82%
QTD
-3.04%
Financial performance
How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$302,000
Gross profit
$302,000
Operating income
-$299.04M
Net income
-$269.95M
Gross margin
100%
Net margin
-89,387.1%
The operating margin has decreased by 22% YoY and by 6% QoQ
Viridian Therapeutics's net margin has decreased by 18% YoY and by 5% QoQ
The operating income has declined by 18% year-on-year and by 6% since the previous quarter
The net income has contracted by 14% YoY and by 5% from the previous quarter
Growth
What is Viridian Therapeutics's growth rate over time
Valuation
What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
1.54
P/S
2,937.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,264.89
Viridian Therapeutics's EPS has increased by 21% YoY but it has decreased by 6% QoQ
The equity has soared by 52% YoY but it fell by 5% QoQ
The price to book (P/B) is 30% less than the 5-year quarterly average of 2.1 and 22% less than the last 4 quarters average of 1.9
The P/S is 122% more than the 5-year quarterly average of 1273.6 but 29% less than the last 4 quarters average of 3978.0
VRDN's revenue is down by 3.8% YoY
Efficiency
How efficient is Viridian Therapeutics business performance
Viridian Therapeutics's return on invested capital has increased by 42% YoY and by 6% QoQ
The company's return on equity rose by 37% YoY and by 4.8% QoQ
The return on assets rose by 35% year-on-year and by 4.8% since the previous quarter
Viridian Therapeutics's return on sales has decreased by 18% YoY and by 5% QoQ
Dividends
What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRDN.
Financial health
How did Viridian Therapeutics financials performed over time
Viridian Therapeutics's total assets has surged by 51% YoY but it has decreased by 3.8% QoQ
The total liabilities has increased by 46% YoY and by 10% QoQ
Viridian Therapeutics's debt is 97% lower than its equity
The equity has soared by 52% YoY but it fell by 5% QoQ
The debt to equity has contracted by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.